Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...
AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...
Cargo was founded by two highly acclaimed cell-therapy researchers. The company raised over $500 million to develop ...
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
But the company said the “severity” of the patient’s case had not previously been seen with the therapy, called Elevidys. It’s the first known patient death with the therapy, which has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback